Free Trial
NASDAQ:MIRA

MIRA Pharmaceuticals Q1 2026 Earnings Results & Report

MIRA Pharmaceuticals logo
$0.66 -0.02 (-3.52%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$0.65 -0.01 (-1.84%)
As of 05:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MIRA Pharmaceuticals reported Q1 2026 earnings on May 14, 2026. The company reported EPS of -$0.03.

Earnings Announcement Details

Quarter
Q1 2026
Report Date

MIRA Pharmaceuticals EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 7 quarters

MIRA Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

MIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

MIRA Pharmaceuticals Q1 2026 Earnings FAQ

MIRA Pharmaceuticals (NASDAQ:MIRA) reported earnings of -$0.03 per share for Q1 2026. The report was announced on Thursday, May 14, 2026.

MIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for MIRA Pharmaceuticals on the company's earnings history page.

MIRA Pharmaceuticals Earnings Headlines

Elon's next millionaires start October 24?
SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.tc pixel
See More MIRA Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s pipeline is centered on novel pharmaceutical compounds intended to address conditions involving anxiety, cognitive impairment, depression and pain.

MIRA’s lead programs include MIRA-1a, an investigational synthetic cannabinoid designed for potential use in neurological and psychiatric conditions, and MIRA-3, an oral ketamine analog being developed for potential applications in depression and pain management. These candidates remain in development and have not been approved for commercial use.

Based in Miami, Florida, MIRA Pharmaceuticals is focused primarily on advancing its drug candidates through preclinical and clinical development rather than selling marketed products. The company is led by Chief Executive Officer Erez Aminov and is pursuing pharmaceutical development opportunities for patients in the United States and broader international markets.

View MIRA Pharmaceuticals Profile